Abstract Library

#4189 Pit and pitfalls of tumor mutational burden assessment in well-differentiated pancreatic neuroendocrine tumors: Two case reports from University of Verona

Introduction: The hypermutated phenotype is used as a predictive parameter for immune-checkpoint inhibitors (ICI). However, the relationship between high TMB, the underlying mutational drivers and response to ICI is still unclear.

Conference:

Presenting Author: Trevisani E

Authors: Torresan I, Reni A, Trevisani E, Borghesani M, Rossi A,

Keywords: Neuroendocrine tumor, NGS, Tumor Mutational Burden, Alkylating agent, DNA Damage Repair, Liquid biopsy,

#4182 DNA damage repair genes alterations in pancreatic neuroendocrine tumor treated with Temozolomide

Introduction: Temozolomide (TMZ), a standard therapy for pancreatic neuroendocrine tumors (pNETs), is an alkylating agent causing missense mutations and triggering cell death.

Conference:

Presenting Author: Trevisani E

Authors: Trevisani E, Reni A, Torresan I, Borghesani M, Rossi A,

Keywords: DNA Damage Repair, Tumor mutational burden, Neuroendocrine, Temozolomide,

#4176 A single center experience of locoregional treatments application in neuroendocrine liver metastases

Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are complicate with neuroendocrine hepatic metastasis (NELM) in approximately 60% of cases. Loco-regional interventional radiology procedures are widely approved in treatment of hepatocellular carcinoma (HCC) and in last years found more and more application in liver metastasis.

Conference:

Presenting Author: Ferretti S

Authors: Masoni B, Ferretti S, Rossi R, Ceriani R, Laffi A,

Keywords: neuroendocrine, loco regional treatment, liver metastasis, interventional radiology, embolization, ablation,

#4091 Grade 2 (G2) gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs): Risk stratification beyond Ki-67?

Introduction: G2 GEP-NETs are well-differentiated neuroendocrine neoplasms with Ki-67 proliferation index of 3-20%. Rather than behaving as a monolithic category, these neoplasms are often characterized by an unpredictable outcome, and additional biomarkers are needed.

Conference:

Presenting Author:

Authors: Laffi A, Zerbi A, Lavezzi E, Carrara S, Rossi E,

Keywords: GEP NET, G2, neuroendocrine tumor, neuroendocrine,

#4073 Comparative targeted NGS analysis between solid and liquid biopsies in GEP-NET: A pilot study

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present a broad clinical variability. Genetic profile could be a striking resource to respond to prognostic and treatment purposes. Sequencing of circulating tumor DNA (ctDNA) from liquid biopsy (LB) has been proposed as a less invasive alternative to solid biopsy (SB).

Conference:

Presenting Author:

Authors: Gagliardi I, Borges de Souza P, Martiradonna M, Rossi L, Albertelli M,

Keywords: Genetic profile, Liquid biopsy, Solid biopsy, GEP-NET, ctDNA,